Novo Nordisk A/S (NONOF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bagsvaerd, Denmark. The current CEO is Maziar Mike Doustdar.
NONOF has IPO date of 2010-05-07, 77,406 full-time employees, listed on the Other OTC, a market capitalization of $172.47B.
Novo Nordisk A/S is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates through two primary segments: Diabetes and Obesity Care, which includes insulins, GLP-1 therapies, oral antidiabetic products, and obesity treatments; and Biopharmaceuticals, which focuses on haemophilia, growth disorders, and hormone replacement therapy. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk maintains strategic collaborations with industry partners including Gilead Sciences and Lumen Bioscience to advance its pipeline in cardiometabolic disease treatments.
